Trial · NCT03178643
Registered outcomes15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 15 of 15
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of Clinical Malaria Per Patient Year | 12 months | The primary endpoint is the cumulative incidence of clinical malaria expressed as episodes per person-year at risk. Time at risk will begin when study participants are randomized and receive study drug (i.e. begin chemoprevention) and end when participants reach the end of the observation period. |
| Secondary | Number of Participants With Severe Anemia | 12 months | E.g., hemoglobin \<5.5 g/dL |
| Secondary | Number of Participants With Severe Malaria | 12 months | Positive rapid diagnostic test (RDT). |
| Secondary | Number of Participants With Hospitalization for Malaria | 12 months | Patient admitted to hospital for malaria with confirmed positive RDT. |
| Secondary | Number of Participants With Light Microscopy (LM)-Positive Malaria | 12 months | LM-positive malaria defined as the reported presence of P. falciparum parasites detected by LM irrespective of RDT or other detection results. |
| Secondary | Number of Participants With Unconfirmed Malaria | 12 months | Defined as the receipt of antimalarials for suspected malaria episodes that were not confirmed by any objective diagnostic test. |
| Secondary | Number of Participants With Fatal Malaria | 12 months | Defined as death during hospitalization for malaria with positive RDT. |
| Secondary | Number of Participants With Asymptomatic Parasitization | 12 months | Defined as the presence of parasites during routine follow-up visits as detected by PCR in patients without fever or a history of recent fever. |
| Secondary | Number of Participants With Painful Events | 12 months | Pain lasting two hours or more without obvious cause. |
| Secondary | Number of Participants With Dactylitis | 12 months | Pain or tenderness with or without swelling of the hands or feet. |
| Secondary | Number of Participants With Transfusions | 12 months | Receipt of RBCs (red blood cells) from any caregiver for any indication. |
| Secondary | Number of Participants With Acute Chest Syndrome | 12 months | Defined as a new pulmonary infiltrate and at least 3 of the following findings: chest pain, temperature elevation \> 38.5°C, tachypnea, wheezing, or cough. |
| Secondary | Number of Participants With All-cause Hospitalization | 12 months | Hospitalization at HBCH or any other inpatient facility with any admitting diagnosis. |
| Secondary | All-cause Deaths | 12 months | Death by any cause. |
| Secondary | Molecular Markers of Malaria Parasite Drug Resistance | 12 months | presence of SNPs in parasite genes that confer resistance to the study drugs |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03178643/registered